Product news from the 01/02/07 news brief
The FDA has approved Janssen’s Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia. The once-daily oral medication is specifically designed to deliver paliperidone -- the active ingredient derived from risperidone -- through the innovative OROS(R) extended-release technology, demonstrating powerful efficacy and a proven safety and tolerability profile.
The FDA approved BioForm Medical’s Radiesse, a cosmetic dermal filler for the long-lasting correction of moderate to severe facial wrinkles and folds. Radiesse also received FDA approval for the correction of facial fat loss in patients with HIV.